Sanofi pledges Euro 50m to boost life sciences research
French drugmaker Sanofi-aventis has formed a research partnership with the French Life Sciences and Healthcare Alliance (AVIESAN), to boost research in areas such as ageing, immuno-inflammatory diseases, infectious diseases and regenerative medicine.
French drugmaker Sanofi-aventis has formed a research partnership with the French Life Sciences and Healthcare Alliance (AVIESAN), to boost research in areas such as ageing, immuno-inflammatory diseases, infectious diseases and regenerative medicine.
Sanofi also has entered a corporate sponsorship agreement to support researchers who set up their research laboratory in France.
The drugmaker will invest Euro 50m into these partnerships over five years.
AVIESAN includes the National Centre for Scientific Research (CNRS), the National Institute of Health and Medical Research (INSERM), the Institut Pasteur, the Institute of Research for Development (IRD), the Conference of University Presidents (CPU) and the Conference of regional and university hospital chief executives.
This is the first time such a partnership has been signed with all the players of the academic research community in the field of healthcare in France.
"We are sure that this fruitful collaboration will boost innovation in life sciences in France and ultimately lead to major discoveries that will benefit patients," said Christopher Viehbacher, chief executive of Sanofi-aventis.